Diarrhea News and Research

Latest Diarrhea News and Research

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

With rates of Clostridium difficile (C. difficile) now rivaling drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA) as the most common bacteria to cause healthcare-associated infections, new expert guidance encourages healthcare institutions to implement and prioritize prevention efforts for this infectious diarrhea.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures.

From Evident Corporation - Life Sciences 5 May 2014

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).

30 Apr 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

Children with ASD more likely to experience general gastrointestinal complaints

A new study conducted by researchers at Marcus Autism Center, Children's Healthcare of Atlanta and Emory University School of Medicine indicates that children with autism spectrum disorder (ASD) are more than four times more likely to experience general gastrointestinal (GI) complaints compared with peers, are more than three times as prone to experience constipation and diarrhea than peers, and complain twice as much about abdominal pain compared to peers.

29 Apr 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Use of frozen stool for fecal transplant successfully treats C. difficile infection

Using frozen stool from healthy, unrelated donors was safe and effective in treating patients with serious, relapsing diarrhea caused by Clostridium difficile, according to a new pilot study published in Clinical Infectious Diseases and available online.

25 Apr 2014

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

In the United States, approximately 179 million cases of acute diarrhea occur each year, and most of those cases are entirely preventable, a researcher from The University of Texas Health Science Center at Houston concluded in a New England Journal of Medicine review article.

23 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

Study provides better understanding of intestinal pathologies associated with inherited, infectious diseases

The "brush border" - a densely packed array of finger-like projections called microvilli - covers the surfaces of the cells that line our intestines.

17 Apr 2014

Freiburg researchers discover molecule that smuggles toxins from intestinal pathogens into human cells

Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Freiburg have discovered the receptor responsible for smuggling the toxin of the bacterium Clostridium perfringens into the cell.

17 Apr 2014

Young children suffering from diarrheal diseases less likely to receive ORT in private facilities

Young children suffering from diarrheal diseases are less likely to receive life-saving oral rehydration therapy (ORT) if they seek treatment at private, for-profit clinics, according to the first-ever, large-scale study of child diarrhea treatment practices in sub-Saharan Africa.

16 Apr 2014

Diarrhea News and Research

Latest Diarrhea News and Research

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Teva's SYNRIBO for injection receives FDA approval for home administration

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Children with ASD more likely to experience general gastrointestinal complaints

Adhesion molecule offers promising therapeutic target for preventing colitis

Forest Laboratories enters into definitive agreement to acquire Furiex

Use of frozen stool for fecal transplant successfully treats C. difficile infection

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Study provides better understanding of intestinal pathologies associated with inherited, infectious diseases

Freiburg researchers discover molecule that smuggles toxins from intestinal pathogens into human cells

Young children suffering from diarrheal diseases less likely to receive ORT in private facilities

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in